In which cSSTI patient types do you think ceftaroline is the most valuable and what are the risk factors for poor prognosis?
In this video, Prof. Matthew Dryden describes the treatment of cSSTI, including in which patient types ceftaroline fosamil is most valuable and what are the risk factors associated with its poor prognosis.
This video describes the efficacy of ceftaroline fosamil in high-risk patients, such as those with comorbidities, in the Phase III cSSTI trials (CANVAS 1, CANVAS 2 and COVERS trials).
This video provides information on how the proportion of AEs in ceftaroline fosamil clinical trials compare to that in the real-world experience.
Prof. Matthew Dryden and Prof. Tobias Welte describes clinical trials versus the real-world experience.
In this video, Prof. Christian Eckmann answers the question, ‘How do ceftaroline fosamil requirements regarding routine monitoring and dose adjustment depend on factors such as body weight compared to other agents such as vancomycin?’
This video provides information on considering the appropriate therapy in patients with cSSTI, which was presented in the ZINFORO® Satellite Symposium at the ECCMID 2018 and filmed post event for educational purposes by Prof. Christian Eckmann.
This video describes the MoA of ZINFORO® (ceftaroline fosamil) on the indications CAP and cSSTI.
This video provides information on ceftaroline fosamil in patients with cellulitis in the cheek: Patient Case Animation – Case 2 (cSSTI).
This video provides information on ceftaroline fosamil in patients with cSSTI not responding to the initial treatment: Patient Case Animation – Case 4 (cSSTI).
This video provides information on how ZINFORO® delivers a rapid and potent activity against the key causative pathogens in cSSTI.
In this video, Prof. Matteo Bassetti describes the treatment of cSSTI, including in which patient types ceftaroline fosamil is most
valuable and where ceftaroline fosamil fits into the current treatment pathway.
This video provides information about CANVAS 1 and CANVAS 2, an analysis of clinical response at Day 3 in 2 Phase III trials of ceftaroline fosamil versus vancomycin plus aztreonam in the treatment of cSSTIs.
AE, adverse event; CANVAS, CeftAroliNe Versus vAncomycin in Skin and skin structure infections; CAP, community-acquired pneumonia; COVERS, CeftarOline versus Vancomycin and aztrEonam tReating cSSTI; cSSTI, complicated skin and soft tissue infection; ECCMID, European Congress of Clinical Microbiology and Infectious Diseases; MOA, mode of action.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.